Standard methods for quantifying positron emission tomography (PET) uptake in the aorta are time consuming and may not reflect overall vessel activity. We describe aortic microcalcification activity (AMA), a novel method for quantifying 18F-sodium fluoride (18F-NaF) uptake in the thoracic aorta.
Twenty patients underwent two hybrid 18F-NaF PET and computed tomography (CT) scans of the thoracic aorta less than three weeks apart. AMA, as well as maximum (TBRmax) and mean (TBRmean) tissue to background ratios, were calculated by two trained operators. Intra-observer repeatability, inter-observer repeatability and scan-rescan reproducibility were assessed. Each 18F-NaF quantification method was compared to validated cardiovascular risk scores.
Aortic microcalcification activity demonstrated excellent intra-observer (intraclass correlation coefficient 0.98) and inter-observer (intraclass correlation coefficient 0.97) repeatability with very good scan-rescan reproducibility (intraclass correlation coefficient 0.86) which were similar to previously described TBRmean and TBRmax methods. AMA analysis was much quicker to perform than standard TBR assessment (3.4min versus 15.1min, P<0.0001). AMA was correlated with Framingham stroke risk scores and Framingham risk score for hard cononary heart disease.
AMA is a simple, rapid and reproducible method of quantifying global 18F-NaF uptake across the ascending aorta and aortic arch that correlates with cardiovascular risk scores.
Thoracic aortic calcification is an important pathological entity underlying both intimal atherosclerotic disease and medial degenerative processes.1 High-density macro-calcified lesions in the aortic wall can be readily identified using computed tomography (CT) and are associated with an increased risk of stroke and mortality.1,2,3,4 However, these lesions represent a late and stable stage of vascular wall pathology where active disease processes may have become quiescent.5 In contrast, microcalcification - typically defined as lesions <50 µm - cannot be detected on conventional imaging but can identify regions of active vascular disease.6,718F-Sodium fluoride (18F-NaF) is a positron emitting radiotracer that allows the detection of microcalcification activity by positron emission tomography (PET),8 providing a marker of aortic disease which might further improve risk prediction. Indeed, coronary 18F-NaF PET has recently demonstrated its ability to improve risk prediction beyond that afforded by CT calcium score.9,10 Thus, there is interest in developing summary quantitative methods of measuring 18F-NaF uptake in the aorta, which may provide similarly important prognostic information.
Quantification of 18F-sodium fluoride uptake in the thoracic aorta currently involves labour intensive analysis of multiple regions of interest across sequential axial slices and calculating mean and maximum intensity uptake values. These values are then normalized to blood pool activity to generate mean (TBRmean) and maximum (TBRmax) tissue to background ratios respectively.11,12,13 Typically, TBRmax values are influenced by only a small number of the most intense pixels within a volume of interest and may not accurately reflect the overall PET activity within that volume (Figure 1). A simple, robust and time-efficient technique that could provide a summary measure of PET uptake across the thoracic aorta would be a major advance. We, therefore, aimed to develop a novel method of quantifying the burden of 18F-NaF uptake across both the ascending aorta and aortic arch (aortic microcalcification activity, AMA) and to assess its repeatability, reproducibility and time-efficiency compared with current standard approaches. Finally, we provide a comparison between each method and well validated clinical risk scores for future risk of cardiovascular events.14,15
Twenty patients recruited as part of the Dual anti-platelet therapy to Inhibit Atherosclerosis and Myocardial Injury in patients with Necrotic high-risk coronary plaque Disease (DIAMOND NCT02110303) study underwent two hybrid 18F-NaF PET-CT scans of the thoracic aorta no more than three weeks apart.16,17 Inclusion criteria for the study were patients ≥ 40 years old with angiographically confirmed multivessel coronary disease defined as epicardial vessels with >50% stenosis or having undergone previous coronary revascularisation. Exclusion criteria included acute coronary syndrome in the preceding 12 months, revascularisation in the preceding 3 months, estimated glomerular filtration rate <30 mL/min/1.73m2, concurrent therapy with oral anticoagulants or thienopyridine (clopidogrel or prasugrel), or known allergy to iodine contrast media. The study was approved by the local institutional review board, the Scottish Research Ethics Committee (REC reference: 14/SS/0089), the Medicines and Healthcare products Regulatory Agency, and the United Kingdom Administration of Radiation Substances Advisory Committee and written informed consent was acquired from all patients. The present work is a post-hoc analysis of this prospective randomised controlled trial.
PET-CT Image Acquisition Protocol
All scans were performed 60 min after injection of 250 MBq of 18F-NaF on a hybrid PET-CT scanner (128-multidetector Biograph mCT, Siemens Medical Systems, Erlangen, Germany) at a single centre. Attenuation correction CT was performed immediately before PET data acquisition (100-120 kV, current 40-50 mA), and reconstructed at 3-mm slice thickness. The field of view incorporated the heart and whole thoracic aorta including the first branches of the head and neck vessels. PET data were acquired with ECG-gating in list-mode during a single 30-min bed position.
Positron Emission Tomography Reconstruction
PET images were reconstructed into four cardiac phases. All PET image reconstructions were performed using the UHD algorithm which applies point-spread function and time-of-flight techniques on a 256 × 256 matrix (109 slices, slice thickness 2.027 mm) using 2 iterations, a 5-mm Gauss filter and 21 subsets. Initial analysis was performed by analysing uptake throughout the cardiac cycle (summed gate). However, we have demonstrated improved repeatability and reproducibility with correction for heart movement and blood pool clearance when assessing coronary arteries.18 As such, motion-corrected images of the ascending aorta and arch were also obtained applying the same custom-built algorithm as used in the coronary vessels for quantifying PET uptake (FusionQuant v1.20.05.14, Cedars-Sinai Medical Centre, Los Angeles).19 This motion correction function aligns the aortic uptake from all gates throughout the cardiac cycle onto the mid-diastolic gate without data loss. Finally correction for blood pool clearance and the time interval between 18F-NaF injection and scan acquisition were performed as described previously and applied to the background (blood-pool) activity.20
Assessment of Aortic 18F-Sodium Fluoride Uptake
Conventional methods for assessing aortic uptake were investigated alongside AMA using FusionQuant v1.20 software as described below (Cedars-Sinai Medical Centre, Los Angeles).21 For all the methods, the PET signal was first carefully co-registered in 3 orthogonal planes using the non-contrast attenuation CT in all patients. Background activity in the blood pool was determined as the average standardised uptake value (SUVmean) of two 2-cm3 spheres of interest, one in the right atrium and one in the left atrium. The time to complete image analysis was recorded for all of the methods investigated.
Aortic microcalcification activity measurements
We modified the recently published technique for assessing global 18F-NaF uptake across the coronary arteries22,23 for use in the ascending aorta and aortic arch. Aortic 18F-NaF activity was measured within volumes of interest created around the aorta using a centreline function in a multiplanar reconstruction viewer (Figure 2). The final diameter of the ROI around the aorta was equal to the maximal luminal diameter of the aorta of that section plus 4 mm (the approximate spatial resolution of PET). This margin of error can be consistently drawn and was added because the spatial resolution of PET is limited, PET and CT may be misregistered, and tracer uptake is frequently highest around the outer perimeter of the vessel. The ascending aortic volume of interest started at the sinotubular junction and finished immediately proximal to the junction with the brachiocephalic artery. The aortic arch volume of interest started at the junction with the brachiocephalic artery and finished immediately distal to the junction with the left subclavian artery. The descending aorta was not quantified during this analysis due to overspill of 18F-NaF uptake originating from the adjacent thoracic spine.
Aortic microcalcification activity (AMA) represents the ratio of aortic activity to background radiotracer activity. Aortic activity is calculated by taking the cumulative voxel intensity in the aortic volumes of interest and dividing by the volume in cm3, to give aortic intensity per cm3. The background radiotracer activity is similarly calculated by dividing the cumulative radiotracer activity in the two 2-cm3 atrial volumes of interest, and dividing by the volume, giving background voxel intensity per cm3 (Figure 2). AMA is calculated by dividing aortic intensity per cm3 by background intensity per cm3 as a unitless number. Contamination from the sternum or clavicular bones was excluded by applying an upper voxel intensity limit to the AMA. This threshold is set at the SUVmax in a volume of interest out-with the sternum, excluding all values above it in calculations of AMA.
Whole vessel standardised uptake values and tissue to background ratios
Established methods for calculating whole vessel SUVmean and SUVmax were applied using methodology for the ascending aorta and aortic arch described previously.12,24 Briefly, on adjacent axial images, A series of 2-D regions of interest were drawn around the aorta on adjacent 3-mm slices beginning where the right pulmonary artery is first visible, finishing at the last slice in which the aortic arch is visible. The average SUVmean and SUVmax over all regions of interest (typically between 30 and 40 slices) were calculated (Figure 1). Tissue to background ratios (TBRs) were also calculated for each region of interest - performed by dividing SUVmean and SUVmax values by blood pool activity (TBRmean and TBRmax, respectively). TBR values were similarly averaged over all regions of interest for whole vessel TBRmean and TBRmax.
Most diseased segment standardized uptake values and tissue to background ratios
As described previously, using the same regions of interest drawn in whole vessel analysis, the most diseased segment approach considers only the three consecutive regions of interest with the highest mean (SUVMDSmean and TBRMDSmean) and max (SUVMDSmax and TBRMDSmax) values and therefore represents uptake in the single most intense lesion.13,25
Observer Repeatability and Scan-Rescan Reproducibility
All baseline scans were interpreted by two trained observers (AF and ML) using all techniques described above (AMA, whole vessel analysis, most diseased segment). The 20 repeat scans were analysed for all methods by one of the trained observers (AF or ML), blinded to the original results, in a random order and more than 4 weeks after the first analysis of the baseline scans to minimise recall bias.
Time Efficiency Analysis
In 10 randomly selected cases, the time taken to conduct each method (whole vessel analysis, most diseased segment and AMA) were recorded separately. The time taken to measure blood pool activity was excluded from the analysis as this is common to all techniques.
Framingham stroke risk score and Revised Framingham stroke risk score are validated risk scores for predicting the 10-year risk of stroke.15,26 Framingham risk score for hard coronary heart disease and American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease (ACC/AHA ASCVD) score are validated risk scores for predicting the 10-year risk of coronary events and cardiovascular events respectively.27,28 Each of these scores were calculated for each participant and the correlation with PET assessments of aortic 18F-NaF activity investigated.
All statistical analyses were performed in the open-source statistical software package R (V4.0.2). Continuous variables with normal distribution were presented as mean ± standard deviation, whereas non-normally distributed variables were presented as median [interquartile range]. Categorical variables were presented as number (percentage). Intra- and inter-observer variability as well as scan-rescan reproducibility were assessed using for each 18F-NaF aortic uptake method using mean error, 95% limits of agreement, coefficient of reproducibility, intraclass correlation coefficient and Bland-Altman plots.29 Associations between clinical risk scores and PET uptake methods were evaluated as a continuous variable (Pearson’s correlation coefficient). Statistical significance was taken as a two-sided P<0.05.
18F-Sodium fluoride uptake was present in the ascending aorta and aortic arch of all twenty patients (Table 1). Uptake was seen in the aortic wall, although the pattern and degree of uptake varied markedly between patients (Figure 3). The AMA method was nearly 5 times quicker to perform than TBR analyses (3.4±0.5 versus 15.1±1.7 min, P<0.0001)
Intra-observer Repeatability of Aortic Microcalcification Activity
The AMA values ranged from 0.91 to 1.51 with a mean of 1.08±0.14. The intra-observer repeatability was excellent (intraclass correlation coefficient 0.98), with mean error 0.00, 95% limits of agreement of − 0.06 to 0.06, and coefficient of repeatability of 0.05. These results are similar to intra-observer repeatability for whole vessel and most diseased segment methods (Table 2, Supplementary Figure 1).
Inter-observer Repeatability of Aortic Microcalcification Activity
The inter-observer repeatability was excellent (intraclass correlation coefficient 0.97) with a mean error of 0.01, narrow 95% limits of agreement of − 0.05 to 0.07, and a coefficient of repeatability of 0.08 (Table 2, Supplementary Figure 2). Again, similar inter-observer repeatabilities were seen for whole vessel and most diseased segment methods (Table 2, Supplementary Figure 2).
Scan-Rescan Reproducibility of Aortic Microcalcification Activity
The AMA method demonstrated very good scan-rescan reproducibility (intraclass correlation coefficient 0.86) with a minimal mean error of 0.00, narrow 95% limits of agreement of − 0.13 to 0.13, and a coefficient of reproducibility of 0.11 (Table 2, Figure 4). The scan-rescan reproducibility of AMA was similar to the whole vessel TBRmean (intraclass correlation coefficient 0.84) and TBRmax (intraclass correlation coefficient 0.86) as well as most diseased segment TBRMDSmean (intraclass correlation coefficient 0.83) and TBRMDSmax (intraclass correlation coefficient 0.90, Table 2 and Figure 4).
Scan-rescan reproducibility was unaffected by correction for either the time from radiotracer injection to PET imaging or aortic motion during the cardiac cycle (Table 3). The AMA scores were highly co-linear with the other methods, particularly TBRmax (Supplementary Figure 5).
Correlation to Clinical Risk Score for Stroke
There was a moderate and positive correlation between AMA and the Framingham stroke risk score (R = 0.50, P = 0.03, Figure 5), Revised Framingham stroke risk score (R = 0.44, P = 0.05) and Framingham risk Score for hard coronary (R = 0.44, P = 0.05, Table 4). Apparent weaker associations were observed between the other PET measures and Framingham stroke risk score (Figure 5) and revised Framingham stroke risk score (Table 4). As well as AMA, most diseased segment TBRmax demonstrated a moderate correlation with Framingham risk score for hard coronary heart disease (R = 0.48, P = 0.03). No risk scores correlated with the American College of Cardiology/American Heart Association atherosclerotic cardiovascular score (ACC/AHA ASCVD, Table 4).
Molecular imaging techniques are increasingly being used for investigating disease activity in the cardiovascular system. We describe a novel method, AMA, which quantifies 18F-NaF across both the ascending aorta and aortic arch, providing a measure of overall burden of disease activity in these vessels. We demonstrate this method as being highly reproducible and more time efficient than the whole vessel technique. Moreover, it can be performed with a non-contrast CT, and does not require advanced post-processing techniques, such as motion or time-delay correction, making it potentially more widely applicable. Finally, out of all methods assessed, AMA had the strongest correlation with Framingham stroke risk score and the revised Framingham stroke risk score. These results pave the way for future research investigating whether AMA holds advantages in terms of tracking disease progression and response to therapy as well as improving the prognostic performance of aortic PET.
There are several conceptual advantages to providing a more global assessment of 18F-NaF activity across the aorta than is provided by standard approaches. The TBRmax values in particular are based upon a small number of highly intense pixels and provide information about the peak intensity of a lesion. On the other hand, AMA incorporates both voxel intensity and volume, providing a global quantification of disease burden. These two approaches may have strengths under differing circumstances. For example, the whole vessel TBRmax and most diseased segment approaches may be more helpful in assessing diseases that are initiated by a threshold effect, such as plaque rupture or aortic dissection. In contrast, other diseases may be best captured by describing the overall burden of disease and AMA, such as aneurysm expansion or aortitis. However, theoretical application of such approaches does have limitations and depends on a number of factors. For example, we recently demonstrated that the summary measure of coronary microcalcification activity was the strongest predictor of future coronary events in patients with multivessel disease.9 This probably reflects the fact that plaque rupture commonly heals spontaneously without causing myocardial infarction and therefore a measure of overall disease activity is more powerful than focusing on a single lesion TBRmax. Whether a single intense lesion or overall disease activity better reflects risk of subsequent events in thoracic aortic disease, such as stroke in atherogenic patients or complications of thoracic aneurysm disease, remains to be seen.
In contrast to our findings in the coronary arteries,18 background and motion corrections make minimal difference to overall AMA reproducibility. The time-delay blood pool correction accounts for the different elimination rates between the coronary arteries and blood pool seen over time.18,20 However, the elimination rates for the aorta over the same periods are different to those seen in the coronaries (Supplemental Figure 3). The time-delay blood pool correction formula used in coronary microcalcification activity should, therefore, not be applied to the AMA measurements. Motion correction is necessary in assessing the uptake in the coronary arteries as they are relatively small vessels, with potential contamination from surrounding structures (e.g. mitral valve annular calcification), partial volume effects and marked movement throughout the cardiac cycle. The aorta, on the other hand, is a large and relatively stationary vessel, with little contamination from surrounding structures and reduced suseptability to potential partial volume effects, although these still may be present. Moreover, our technique for drawing AMA volumes of interest was standardised to 4 mm beyond the maximal lumen diameter, likely incorporating most aortic movement. This probably explains why motion correction had no effect on AMA values.
It is important to highlight some limitations to our study. Due to well documented problems with spinal contamination influencing accurate 18F-NaF assessment in the descending thoracic aorta, we chose to limit our AMA analysis to the ascending aorta and aortic arch. Importantly our AMA approach could also be applied to other tracers used to assess disease activity in the aorta (e.g. 18F-FDG or 68Ga-Dotatate), where such contamination is not an issue and where a global assessment of uptake might also include activity in the descending aorta. Although we have demonstrated the favourable efficiency, reproducibility and repeatability of AMA with positive correlations with clinical risk scores, whether or not AMA will improve the prediction of disease progression and cardiovascular events remains to be seen.
New Knowledge Gained
Aortic microcalcification activity is a simple, repeatable and reproducible method for quantifying 18F-NaF uptake in the ascending aorta and arch that is significantly and substantially quicker to perform compared with alternative methods and correlates with validated cardiovascular risk scores.
In conclusion, we have provided a detailed description of how to assess global 18F-NaF activity across both the ascending aorta and aortic arch using a time efficient approach that demonstrates highly favourable repeatability and reproducibility. Studies assessing the ability of AMA to track disease progression and response to therapy as well as predicting cardiovascular outcomes are now required to validate AMA as a novel biomarker of aortic disease.
Aortic microcalcification activity
Positron emission tomography
standardised uptake value
Tissue to background ratio
- TBRMDS :
Most diseased segment tissue to background ratio
Desai MY, Cremer PC, Schoenhagen P. Thoracic aortic calcification: Diagnostic, prognostic, and management considerations. JACC Cardiovasc Imaging 2018;11:1012-26.
Kim J, Budoff MJ, Nasir K, Wong ND, Yeboah J, Al-Mallah MH, Shea S, Dardari ZA, Blumenthal RS, Blaha MJ, Cainzos-Achirica M. Thoracic aortic calcium, cardiovascular disease events, and all-cause mortality in asymptomatic individuals with zero coronary calcium: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2017;257:1-8.
Cho IJ, Chang HJ, Cho I, Heo R, Lee SE, Shim CY, Hong GR, Chung N. Association of thoracic aorta calcium score with exercise blood pressure response and clinical outcomes in elderly individuals: Differential impact of aorta calcification compared with coronary artery calcification. J Am Heart Assoc 2016;5:e003131.
Tison GH, Guo M, Blaha MJ, McClelland RL, Allison MA, Szklo M, Wong ND, Blumenthal RS, Budoff MJ, Nasir K. Multisite extracoronary calcification indicates increased risk of coronary heart disease and all-cause mortality: The Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr 2015;9:406-14.
Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, Carr JJ, Budoff MJ, Allison MA. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA 2014;311:271-8.
Hutcheson JD, Maldonado N, Aikawa E. Small entities with large impact: Microcalcifications and atherosclerotic plaque vulnerability. Curr Opin Lipidol 2014;25:327-32.
Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, Klutmann S. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med 2010;51:862-5.
Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR, Brindle KM, Newby DE, Rudd JH, Davenport AP. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. Nat Commun 2015;6:7495.
Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial 18F-sodium fluoride uptake: A novel marker of plaque biology. J Am Coll Cardiol 2012;59:1539-48.
Kwiecinski J, Tzolos E, Adamson PD, Cadet S, Moss AJ, Joshi N, Williams MC, van Beek EJR, Dey D, Berman DS, Newby DE, Slomka PJ, Dweck MR. Coronary 18F-sodium fluoride predicts outcome in patients with coronary artery disease. J Am Coll Cardiol 2020;75:3061-74.
Blomberg BA, de Jong PA, Thomassen A, Lam MGE, Vach W, Olsen MH, Mali WPTM, Narula J, Alavi A, Høilund-Carlsen PF. Thoracic aorta calcification but not inflammation is associated with increased cardiovascular disease risk: Results of the CAMONA study. Eur J Nucl Med Mol Imaging 2017;44:249-58.
Blomberg BA, Thomassen A, de Jong PA, Simonsen JA, Lam MG, Nielsen AL, Mickley H, Mali WP, Alavi A, Høilund-Carlsen PF. Impact of personal characteristics and technical factors on quantification of sodium 18F-fluoride uptake in human arteries: Prospective evaluation of healthy subjects. J Nucl Med 2015;56:1534-40.
Joshi NV, Toor I, Shah AS, Carruthers K, Vesey AT, Alam SR, Sills A, Hoo TY, Melville AJ, Langlands SP, Jenkins WS, Uren NG, Mills NL, Fletcher AM, van Beek EJ, Rudd JH, Fox KA, Dweck MR, Newby DE. Systemic atherosclerotic inflammation following acute myocardial infarction: Myocardial infarction begets myocardial infarction. J Am Heart Assoc 2015;4:e001956.
Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-8.
D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994;25:40-3.
Moss AJ, Doris MK, Andrews JPM, Bing R, Daghem M, van Beek EJR, Forsyth L, Shah ASV, Williams MC, Sellers S, Leipsic J, Dweck MR, Parker RA, Newby DE, Adamson PD. Molecular coronary plaque imaging using 18F-fluoride. Circ Cardiovasc Imaging 2019;12:e008574.
Moss AJ, Dweck MR, Doris MK, Andrews JPM, Bing R, Forsythe RO, Cartlidge TR, Pawade TA, Daghem M, Raftis JB, Williams MC, van Beek EJR, Forsyth L, Lewis SC, Lee RJ, Shah ASV, Mills NL, Newby DE, Adamson PD. Ticagrelor to reduce myocardial injury in patients with high-risk coronary artery plaque. JACC Cardiovasc Imaging 2020;13:1549-60.
Lassen ML, Kwiecinski J, Dey D, Cadet S, Germano G, Berman DS, Adamson PD, Moss AJ, Dweck MR, Newby DE, Slomka PJ. Triple-gated motion and blood pool clearance corrections improve reproducibility of coronary. Eur J Nucl Med Mol Imaging 2019;46:2610-20.
Doris MK, Otaki Y, Krishnan SK, Kwiecinski J, Rubeaux M, Alessio A, Pan T, Cadet S, Dey D, Dweck MR, Newby DE, Berman DS, Slomka PJ. Optimization of reconstruction and quantification of motion-corrected coronary PET-CT. J Nucl Cardiol 2020;27:494-504.
Kwiecinski J, Berman DS, Lee SE, Dey D, Cadet S, Lassen ML, Germano G, Jansen MA, Dweck MR, Newby DE, Chang HJ, Yun M, Slomka PJ. Three-hour delayed imaging improves assessment of coronary. J Nucl Med 2019;60:530-5.
Massera D, Doris MK, Cadet S, Kwiecinski J, Pawade TA, Peeters FECM, Dey D, Newby DE, Dweck MR, Slomka PJ. Analytical quantification of aortic valve 18F-sodium fluoride PET uptake. J Nucl Cardiol 2018;27(3):962-72.
Tzolos E, Kwiecinski J, Lassen ML, Cadet S, Adamson PD, Moss AJ, Joshi N, Williams MC, van Beek EJR, Dey D, Berman DS, Dweck MR, Newby DE and Slomka PJ. Observer repeatability and interscan reproducibility of 18F-sodium fluoride coronary microcalcification activity. J Nucl Cardiol 2020.
Kwiecinski J, Cadet S, Daghem M, Lassen ML, Dey D, Dweck MR, Berman DS, Newby DE, Slomka PJ. Whole-vessel coronary 18F-sodium fluoride PET for assessment of the global coronary microcalcification burden. Eur J Nucl Med Mol Imaging 2020;47:1736-45.
Dweck MR, Khaw HJ, Sng GK, Luo EL, Baird A, Williams MC, Makiello P, Mirsadraee S, Joshi NV, van Beek EJ, Boon NA, Rudd JH, Newby DE. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J 2013;34:1567-74.
Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A, Investigators d-P. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59.
Dufouil C, Beiser A, McLure LA, Wolf PA, Tzourio C, Howard VJ, Westwood AJ, Himali JJ, Sullivan L, Aparicio HJ, Kelly-Hayes M, Ritchie K, Kase CS, Pikula A, Romero JR, D’Agostino RB, Samieri C, Vasan RS, Chêne G, Howard G, Seshadri S. Revised framingham stroke risk profile to reflect temporal trends. Circulation 2017;135:1145-59.
Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Tomaselli GF, Guidelines ACoCAHATFoP. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013;2014(129):S49-73.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
Vaz S, Falkmer T, Passmore AE, Parsons R, Andreou P. The case for using the repeatability coefficient when calculating test-retest reliability. PLoS ONE 2013;8:e73990.
Authors have no acknowledgments to declare.
The authors have no relevant conflicts of interest to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.
The authors have also provided an audio summary of the article, which is available to download as ESM, or to listen to via the JNC/ASNC Podcast.
AJF (FS/19/15/34155), MBJS (FS/18/31/33676), NLW (FS/19/15/34155), RB (PG/19/40/34422), ET (FS/17/51/33096) and DEN (FS/19/15/34155, CH/09/002, RG/16/10/32375, RE/18/5/34216) are supported by the British Heart Foundation. DEN is also the recipient of a Wellcome Trust Senior Investigator Award (WT103782AIA). AJM is supported by the British Heart Foundation (AA/18/3/34220). MRD is supported by the British Heart Foundation (FS/14/78/31020) and is the recipient of the Sir Jules Thorn Award for Biomedical Research 2015 (15/JTA). EJRVB is supported by SINAPSE (www.sinapse.ac.uk). PDA is supported by a Heart Foundation of New Zealand Senior Fellowship (1844). PS, SC and FusionQuant Development is supported by the National Institute of Health Grant HL135557 (PI: Piotr Slomka). ML is supported by the International PhD programme in Cardiovascular Pathophysiology and Therapeutics (CardioPaTh).
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Fletcher, A.J., Lembo, M., Kwiecinski, J. et al. Quantifying microcalcification activity in the thoracic aorta. J. Nucl. Cardiol. (2021). https://doi.org/10.1007/s12350-020-02458-w
- Image analysis
- Molecular imaging agents